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Abstract: A phase II trial was launched to evaluate if neoadjuvant stereotactic ablative radiotherapy (SABR) before
surgery improves oncologic outcomes in patients with stage I non-small cell lung cancer (NSCLC). We report a
mandated interim safety analysis for the first 10 patients who completed protocol treatment. Operable patients
with biopsy-proven T1-2 N0 NSCLC were eligible. SABR was delivered using a risk-adapted fractionation (54Gy/3
fractions, 55/5 or 60/8). Surgical resection was planned 10 weeks later at a high-volume center (>200 lung cancer
resections annually). Patients were imaged with dynamic positron emission tomography-computed tomography
scans using 18F-fludeoxyglucose (18F-FDG-PET CT) and dynamic contrast-enhanced CT before SABR and again
before surgery. Toxicity was recorded using CTCAE version 4.0. Twelve patients were enrolled between 09/2014 and
09/2015. Two did not undergo surgery, due to patient or surgeon preference; neither patient has developed
toxicity or recurrence. For the 10 patients completing both treatments, median age was 70 (range: 54–76), 60% had
T1 disease, and 60% had adenocarcinoma. Median FEV1 was 73% predicted (range: 54–87%). Median time to
surgery post-SABR was 10.1 weeks (range: 9.3–15.6 weeks). Surgery consisted of lobectomy (n = 8) or wedge
resection (n = 2). Median follow-up post-SABR was 6.3 months. After combined treatment, the rate of acute grade
3–4 toxicity was 10%. There was no post-operative mortality at 90 days. The small sample size included herein
precludes any definitive conclusions regarding overall toxicity rates until larger datasets are available. However,
these data may inform others who are designing or conducting similar trials.
Trial registration: NCT02136355. Registered 8 May 2014.
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Introduction
Stereotactic ablative radiotherapy (SABR, also called
stereotactic body radiation therapy or SBRT) provides a
promising therapeutic option for stage I non-small cell
lung cancer (NSCLC) [1]. Many studies report 3-year
local control rates of approximately 90%, based on post-
treatment imaging [2]. However, the true pathologic
complete response rate (pCR) is unknown. In most
patients, local radiation-induced lung injury (RILI) is evi-
dent on CT after SABR and can impair the detection of
local recurrences [3].
In operable patients undergoing surgery, neoadjuvant
SABR could theoretically provide an oncologic benefit
by decreasing the rate of positive margins, sterilizing the
tumor to avoid the seeding of circulating tumor cells
during surgery [4], or in some cases through an abscopal
effect [5]. The MISSILE-NSCLC study was launched to
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evaluate the oncologic outcomes and toxicity after an a
priori combined treatment approach of SABR followed
by surgical resection, and to determine the pCR rate
after SABR.
To our knowledge, the toxicity of this combined treat-
ment approach has not been previously reported.
Herein, we present the findings of an interim safety
analysis.
Methods
Study design and patient selection
Institutional Research Ethics Board approval was
obtained prior to study initiation, and the study was cen-
trally registered (NCT02136355). Eligible patients had
histologically-confirmed T1 or T2a (≤5 cm) NSCLC,
with no evidence of nodal or distant metastases. Add-
itional requirements included age ≥18, informed con-
sent, Eastern Cooperative Oncology Group (ECOG)
performance status 0–2, life expectancy > 6 months and
a predicted post-operative forced expiratory volume in
1 second (FEV1) of ≥ 30%. Ineligibility criteria included
patients with contraindication to either treatment, previ-
ous lung cancer within the past 5 years, previous thor-
acic radiation or a contrast allergy.
Interventions
SABR was delivered according to a risk-adapted proto-
col, with the dose and fractionation dependent on the
size and location of the tumor (54 Gy / 3 fractions,
55 Gy/5 fractions or 60 Gy/8 fractions). Treatment was
delivered every second day regardless of the dose-
fractionation regimen [6, 7]. A 4-D CT simulation scan
was acquired for all patients. Respiratory gating was con-
sidered in cases where motion was > 7 mm in any
direction.
The gross tumor volume (GTV) was defined as the
visible tumor on CT imaging ± PET, and an internal
GTV encompassed the GTV from all phases of respir-
ation. No additional margin was included for micro-
scopic spread of disease. A planning target volume
(PTV) margin of 5 mm was used. The prescription point
was approximately the 80% isodose line surrounding the
PTV, with the requirement that 95% of the PTV was
covered by 100% of the prescription dose.
Surgical resection was planned to occur at 10 ± 2 weeks
following SABR and consisted of a lobectomy or sublo-
bar resection by either an open or video-assisted thora-
coscopic approach. All patients received sampling of
high risk hilar and mediastinal lymph nodes at the time
of resection. All procedures were done at a high-volume
tertiary surgical centre, with a case volume of >200 lung
resections annually.
Patients with pathologic node-positive disease (N1,
N2, or N3) were referred for adjuvant chemotherapy.
For patients with N2 or N3 disease, adjuvant radiother-
apy to the mediastinum was to be considered as long as
there was minimal overlap with the SABR dose
distribution.
The trial protocol mandated that after 10 patients have
been accrued and completed surgery, a safety analysis to
review treatment toxicity would be undertaken separ-
ately by the study team and the data safety monitoring
committee.
Results
Twelve patients were enrolled between September 2014
and September 2015. Two did not undergo surgery
following SABR due to concerns regarding medical oper-
ability: one continued to smoke more than two packs
per day; the other had unrelated upper gastrointestinal
dysfunction and possible gastroparesis resulting in poor
functional status. Neither patient has developed toxicity
or recurrence.
Patient & treatment characteristics
For the 10 patients completing combined therapy, the
median age was 70 (range: 54–76), 60% had T1 disease,
and 60% had adenocarcinoma. Median FEV1 was 73%
predicted (range: 54–87%). Median time to surgery post-
SABR was 10.1 weeks (range: 9.3–15.6 weeks). Most
patients underwent a lobectomy (n = 8) post-SABR, with
the remainder receiving a wedge resection (n = 2). Me-
dian follow-up post-SABR was 6.3 months.
Outcomes
A total of 24 toxicities were reported (Table 1). The
most common toxicity was pain (grade 1–2), occurring
in 90% of patients. Fatigue, pneumonia and pneumo-
thorax each occurred in 20% of patients. There were 3
recorded grade 3–4 toxicities (pneumonia, atrial fibrilla-
tion and respiratory failure), all in the same patient, and
all of which resolved. The highest grade of toxicity for
each of the 10 patients is shown in Table 2. There were
no deaths within 30 or 90 days of surgery.
Discussion
Neoadjuvant radiotherapy is part of standard treatment
for certain cancers (e.g. rectal cancers, sarcomas), with
the goal of reducing the risk of local recurrence or mar-
gin positivity. In stage I NSCLC, neoadjuvant ablative
therapy has previously been explored using radiofre-
quency ablation (RFA) prior to surgical resection. How-
ever, the high prevalence of viable tumor cells after RFA
(62% of cases) discouraged its widespread adoption [8].
Although prior studies have evaluated salvage surgery in
selected patients who developed local recurrence after
SABR [9–12], the use of a combined approach upfront
has not been assessed previously.
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While the sample size in this interim report is small,
the toxicity rates reported herein compare favorably with
those in prospective studies evaluating surgery alone. In
a pooled analysis looking at two randomized studies
comparing SABR versus lobectomy, the rate of grade 3–
5 toxicity after lobectomy was 48% [13]. Toxicity rates
appear to be lower after sublobar resection, often re-
ported as approximately 30% [14]. However, compari-
sons across trials are subject to bias based on differences
between study populations and treatments.
There is a strong relationship between hospital volume
and surgical toxicity in NSCLC [15], and therefore the
generalizability of these data to low-volume centers is
unknown. In addition, the small sample size included
herein precludes using the toxicity data to inform clin-
ical practice until larger datasets are available. However,
these data, compiled as a mandated interim safety
report, are still informative. They sufficiently assure us it
is safe to continue with combined treatment on the
present clinical trial, which also provides reassurance to
other groups who are designing or conducting similar
trials. Furthermore, these promising early results
generate valuable academic discussion, which garner
interest in an understudied area and primes interested
parties to the forthcoming results of the present trial. If
there is a demonstrable benefit to combined treatment,
there will be a need for validation studies to confirm a
potential shift in practice patterns. If results are negative,
other groups may reexamine the concept with alterna-
tive methodology. In either case, subsequent steps will
require time. By inciting discussion now we hope to ex-
pedite our ability to answer important clinical questions
that ultimately inform the best possible care for our
patients.
Conclusion
In conclusion, toxicity rates after combined SABR and
surgical resection compare favorably with reported rates
in prospective studies of surgical resection alone. While
these findings are preliminary, and certainly inadequate to
inform clinical practice, it provides an early assessment of
the tolerability of combined treatment as we await mature
data on pCR rates and oncologic outcomes.
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Table 1 Type and grade of patient-reported toxicities
Toxicity Number of Patients Reporting Toxicity by Gradea
(N = 24 total toxicities)
Total
1 2 3 4 5
Pain 2 7 0 0 0 9
Fatigue 2 0 0 0 0 2
Pneumonia 0 1 1 0 0 2
Pneumothorax 0 2 0 0 0 2
Atrial Fibrillation (uncontrolled) 0 0 0 1 0 1
Dyspnea 1 0 0 0 0 1
Respiratory failure 0 0 0 1 0 1
Post-Operative Bleeding 1 0 0 0 0 1
Broncho-pleural Fistula 0 1 0 0 0 1
Generalized Weakness 1 0 0 0 0 1
Nausea 0 1 0 0 0 1
Vomiting 0 1 0 0 0 1
Anorexia 1 0 0 0 0 1
aNote: Some patients developed >1 toxicity
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